These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17307054)

  • 1. Role of insulin resistance and hyperglycemia in the development of atherosclerosis.
    Bansilal S; Farkouh ME; Fuster V
    Am J Cardiol; 2007 Feb; 99(4A):6B-14B. PubMed ID: 17307054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance and atherosclerosis.
    Nigro J; Osman N; Dart AM; Little PJ
    Endocr Rev; 2006 May; 27(3):242-59. PubMed ID: 16492903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases.
    Cersosimo E; DeFronzo RA
    Diabetes Metab Res Rev; 2006; 22(6):423-36. PubMed ID: 16506274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction in insulin resistance and type 2 diabetes.
    Jansson PA
    J Intern Med; 2007 Aug; 262(2):173-83. PubMed ID: 17645585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: diabetes and atherosclerosis--running on a common road.
    Federici M; Lauro R
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():11-5. PubMed ID: 16225464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endothelial dysfunction in diabetes mellitus.
    Pănuş C; Moţa M; Vladu D; Vanghelie L; Răducanu CL
    Rom J Intern Med; 2003; 41(1):27-33. PubMed ID: 15529582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity.
    Bakker W; Eringa EC; Sipkema P; van Hinsbergh VW
    Cell Tissue Res; 2009 Jan; 335(1):165-89. PubMed ID: 18941783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, metabolic syndrome and endothelial dysfunction.
    Bigazzi R; Bianchi S
    J Nephrol; 2007; 20(1):10-4. PubMed ID: 17347967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D; Nyström T
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species.
    Duncan ER; Walker SJ; Ezzat VA; Wheatcroft SB; Li JM; Shah AM; Kearney MT
    Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1311-9. PubMed ID: 17711985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.
    Dandona P; Ghanim H; Chaudhuri A; Mohanty P
    J Diabetes Complications; 2008; 22(1):62-75. PubMed ID: 18191079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endothelial dysfunction in diabetes].
    Nishio Y
    Nihon Rinsho; 2010 May; 68(5):823-6. PubMed ID: 20446576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
    Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance.
    Nyström T
    Horm Metab Res; 2008 Sep; 40(9):593-606. PubMed ID: 18792870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance.
    Rask-Madsen C; King GL
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):487-96. PubMed ID: 15637306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance and atherosclerosis.
    Raghavan VA
    Heart Fail Clin; 2012 Oct; 8(4):575-87. PubMed ID: 22999241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications.
    Israelian-Konaraki Z; Reaven PD
    Cardiology; 2005; 103(1):1-9. PubMed ID: 15528894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperglycemia and hyperlipidemia are associated with endothelial dysfunction during the development of type 2 diabetes.
    Okon EB; Chung AW; Zhang H; Laher I; van Breemen C
    Can J Physiol Pharmacol; 2007 May; 85(5):562-7. PubMed ID: 17632592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune-mediated oxidative stress and endothelial dysfunction: implications of accelerated vascular injury in type I diabetes.
    Zimmerman MA; Flores SC
    J Surg Res; 2009 Jul; 155(1):173-8. PubMed ID: 18805553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PPAR-gamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats.
    Pandey NR; Benkirane K; Amiri F; Schiffrin EL
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):346-54. PubMed ID: 17577098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.